🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-523972-21-00
Authorised Phase I/II

Study of IBI3009 alone or in combination with other therapies for extensive-stage small cell lung cancer

2025-523972-21-00 · tracked via the Priya Life Science EU tracker
Sponsor
Fortvita Biologics (USA) Inc.
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Respiratory Tract Diseases
Decision date
27/04/2026
Enrollment target
30
Sites
Poland, Denmark, Spain

Condition studied

Extensive-Stage Small Cell Lung Cancer

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-523972-21-00 on CTIS ↗ ← All trials in the EU